MonTa Biosciences

30/10/2019

At M***a Biosciences we have had amazing results on our TLR7 asset MBS8 in immuno oncology with recent IP filing, complete remission in tumor models in both monotherapy and combination theray with good tolerability. This supports our MBS8 lead as the BEST IN CLASS TLR7 asset currently in development for cancer treatment. We are at BioEurope in Hamburg early November to discuss collaboration with biotech and pharma companies on future clinical combination strategies and still have a few meeting slots open. Reach out to us if you have an interesting candidate for combination therapy with our BEST IN CLASS TLR7 asset and want to book one of our last meeting slots.

07/09/2017

A new pharma-biotech deal in the innate immunity Space: The German company Rigontech working on stimulation of the innate immune system using Rig2 agonists was acquired my MSD.
At M***a Biosciences we work on parrallel Technologies targeting other innate receptors to stimulate the innate immune system. Get in contact if you are interested to hear more........
http://rigontec.com/blog/press-releases/

MSD to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology Sep . 06 . 2017 0 Comment Press Releases Posted by Joanne Tudorica KENILWORTH, N.J. & MUNICH, GERMANY, Sept. 6, 2017 – MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK)), and Rigontec to...

25/08/2017

M***a Biosciences is going to Nordic Life Sciences days in mid September to meet with investors and pharma companies to discuss potential partnership opportunities to further develop our immuno technology to boost the immune system of cancer patients to help them fight their cancer. Contact us if you wish to meet or hear more about how to invest or collaborate with us.

A fun pitching event showcasing the best and brightest entrepreneurs, innovators and startup companies emerging from the Nordic Life Science Incubator ecosystem. Read more

11/07/2017

Amazing results using one of the most revolutionary new cancer medicines-and for cancers so hard to treat using traditional treatments
https://www.yahoo.com/beauty/new-cancer-drug-effective-tumors-fda-approved-immediately-164122959.html

“The data was so good, they had to approve it.”

07/07/2017

Cancer Immunotherapy is a cornerstone in modern cancer treatment. Recently the immunotheraputic drug Keytruda was approved in the US as first-line-treatment of lung cancer in combination with existing treatments. IAt M***a Biosciences we foresee that our therapy will also show benefits for the patients by combination with this type of treatment: https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-pembrolizumab-lung-expanded

A Cancer Currents blog post on FDA’s approval of pembrolizumab (Keytruda®) to be used with chemotherapy as a first-line treatment for non-small cell lung cancer.

07/07/2017

I M***a Biosciences arbejder vi med udvikling af nye typer immunterapi til behandling af kræft i kombination med eksisterende behandlinger, så immunsystemet hjælper patienten med at bekæmpe sygdommen. Læs mere her om hvordan immunterapi virker: https://www.cancer.dk/hjaelp-viden/kraeftbehandling/behandlingsformer/immunterapi/

Læs om immunterapi, der er en behandlingsform, hvor man udnytter kroppens eget immunforsvar til målrettet at bekæmpe kræftceller.

30/03/2017

We went to the BioEurope Spring partnering and investor event in Barcelona last week. It was amazing to attract attention from so many of the top 20 large pharma companies and have their view on our technology to improve cancer treatment. We had a huge attention and look very much forward to the next stage in our development to explore the potential for combination treatment in cancer. A great success for M***a biosciences and our technology.

13/03/2017

Vi fejrer investering i M***a Biosciences fra det danske innovationssystem Pre-Seed Innovation-læs pressemeddelelsen her http://medwatch.dk/secure/Medicinal___Biotek/article9415922.ece

Det lille danske biotekselskab M***a Biosciences får friske penge fra innovationsmiljøet Pre-Seed Innovation. Selskabet satser på udvikling af et nyt kræftmiddel, som er designet til aktivt at uddanne kroppens immunforsvar til at genkende og nedkæmpe kræftceller. - Author: STEFAN SINGH KAILAY

13/03/2017

Celebrate our recent investment from Pree-Seed Innovation http://arcticstartup.com/article/cancer-biotech-monta-raises-270000-euros/

Copenhagen-based biotech company M***a BioSciences Aps has raised 270,000 euros from the incubator Pre-Seed Innovation for their promising cancer treatment. The Danish firm has found a method in which the body’s immune system is trained to actively recognize and fight cancer cells. The treatment mak...

03/01/2017

Happy New Year update.
We have been silent on Facebook for some time.
This is NOT because we are lazy, BUT because we have been busy to develop our Cancer Immunotherapy towards testing in patients. We are currently working hard to select exactly the right candidate that will have the strongest anti-cancer activity in patients and the best possibility to benefit patients.

Another very IMPORTANT NEW YEAR update is that we have attracted an investor to develop our technology further. This investment will make us able to reach milestones demonstrating the strength of our technology to support further development.

BUT WE ARE STILL LOOKING FOR ADDITIONAL FUNDING, SPONSORSHIP OR DONATIONS to accelerate our development to be able to help cancer patients earlier. PLEASE get in contact here http://montabiosciences.com/contact-us/
if you are interested to invest, donate or sponsor our efforts to bring the best cancer treatments to the benefit of patients

M***a Biosciences is a start-up biotech Company in the cancer immunotherapy field

20/09/2016

M***a Biosciences has been selected as one of the few companies for the NOME mentoring programme by science incubator Hub in Copenhagen; Accelerace. We are delighted to have managed to be part of this promising programme and look forward to be mentored by two top professional Biotech entrepreneurs and a Venture investor, who have raised more than 200 mio US$ in equity investment and have board seats in major US and EU biotech companies.

11/05/2016

If you want to invest in cancer therapeutics for the future, please contact us at our homepage: www.montabiosciences.com

Our technology take advantage of the immune system instead of destroying it. With our therapy we educate the immune system to recognize and eliminate metastases in the patients, aiming to actually cure the patient.

M***a Biosciences is a start-up biotech Company in the cancer immunotherapy field